Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

Trial Profile

Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 05 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top